Drug Profile
Research programme: antisense therapies - Ionis Pharmaceuticals
Alternative Names: single-stranded RNAi - Ionis; ssRNAi - IonisLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Suzhou Ribo Life Science
- Class Antisense oligonucleotides; Small interfering RNA
- Mechanism of Action Protein synthesis inhibitors; RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Metabolic-disorders in China (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Metabolic-disorders in USA (Parenteral)
- 30 May 2021 Early research for Metabolic disorders is still underway in USA and China